ASCO 2022 | GU cancer highlights at ASCO 2022

Andrei Gafita, MD, University of California, Los Angeles, CA, gives his highlights in the field of genitourinary cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The overall survival (OS) data of the phase II TheraP trial (NCT03392428) of Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer were presented and despite Lu-PSMA-617 not demonstrating significant benefit to survival, there were fewer side effects reported. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.